[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-segmental-glomerulosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-segmental-glomerulosclerosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,46,71,84,108,147,172,186,214,241,269,287,308,334,363,383,412,433,535],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054106","phase-2-an-open-label-phase-2-study-of-n-acetyl-d-mannosamine-mannac-in-subjects-with-primary-focal-segmental-glomerulosclerosis-100054106",false,"NCT06664814","An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis","* INCLUSION CRITERIA:\n\nIndividuals must meet all the following inclusion criteria to be eligible to participate in this study:\n\n* Prior kidney biopsy demonstrating FSGS obtained within 10 years prior to the screening visit.\n* Age \\>=18 years weighing more than 50 kg.\n* If the patient is on immunosuppressive therapy (e.g., prednisone, cyclosporine, tacrolimus or mycophenolate mofetil) he\u002Fshe should be on these medications for at least 3 months prior to study evaluation and should be on a stable dose of the medication for at least 4 weeks before start of trial, with no plans to alter the regimen during 12 weeks of study period, except to stabilize levels and\u002For for any safety concerns.\n* Subjects will be allowed to continue with standard of care (SOC) non-immunosuppressant antiproteinuric agents to include RAAS inhibitors, mineralocorticoid antagonists (MRA), sodium-glucose co-transporter-2 inhibitors (SGLT2i), non-dihydropyridine calcium channel blockers (NDHP-CCBs), and glucagon-like peptide-1 (GLP-1) receptor agonists, in addition to other SOC adjuvant therapies such as diuretics, if they are able to maintain a stable dose throughout the trial. Subjects and their primary nephrologists will be encouraged to optimize their SOC treatments as much as possible prior to trial commencement. Subjects must be on a stable dose for at least 4 weeks before start of trial. Subjects should attempt to keep stable doses of both immunosuppressants and anti-proteinuric drugs throughout trial duration, to avoid confounding effects. Patients not receiving any of these SOC agents either due to allergy or intolerance will still be eligible.\n* Subjects must have a spot random urine PCR of \\>= 2g\u002Fg on each of 3 measurements collected on at least 2 separate days during screening period plus a 24-hr urine protein collection of \\>= 2g\u002Fday. The rationale for using this degree of proteinuria is that proteinuria beyond this threshold value significantly increases the risk of progressive decline of renal functions in the absence of effective therapies to mitigate this risk. Conversely, this threshold value could also allow for the selection of a cohort of patients who are most likely to benefit from ManNAc therapy.\n* Subjects with an estimated glomerular filtration rate (eGFR) \\>=45 mL\u002Fmin\u002F1.73\u002Fm\\^2 using the race-free CKD-EPI 2021 equation based on creatinine and cystatin-C \\[Inker et al, 2021\\]. The rationale is that below this eGFR threshold, sialic acid, the key metabolite of ManNAc markedly accumulates and may potentially result in systemic toxicity. Prior pharmacokinetic studies have shown that renal elimination of sialic acid is primarily through glomerular filtration, and it is neither reabsorbed nor secreted in the renal tubules. Hence decline in eGFR below 45 mL\u002Fmin\u002F1.73m\\^2 directly correlates with rising blood sialic acid levels \\[Fuentes et al, 2020\\], in addition, these subjects may not benefit as much from ManNAc therapy as they have advanced disease pathology, which may be irreversible. Future studies with personalized precision ManNAc dosing may benefit the patient population with eGFR \\\u003C45 mL\u002Fmin\u002F1.73m\\^2.\n* Subjects of reproductive potential must be willing to use at least one effective form of birth control throughout the trial period, unless they have had a permanent birth control procedure\u002Fintervention including but not limited to hysterectomy, tubal ligation and\u002For vasectomy. These may include the following: barrier methods (such as condoms), oral or depot injection (for example, Norplant or Depo-Provera) contraception medication, and\u002For intrauterine devices.\n* Evidence of a personally signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the study and their willingness to comply with all aspects of the study and their willingness to comply with all aspects of the study protocol, including treatment plan, laboratory tests, baseline and follow-up visits and procedures that include completion of daily diaries to record symptoms and medication intake.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Individuals who are unwilling or unable to provide informed consent.\n* Individual presenting for initial therapy of uncontrolled nephrotic syndrome which we define as proteinuria as measured by spot urine protein:creatinine ratio \\>3g\u002Fg or 24-hour urine protein excretion of \\>3.5g\u002Fday with symptomatic peripheral edema or pulmonary edema, hypoalbuminemia (serum albumin \\\u003C3.0g\u002Fdl), electrolyte disturbances (related or unrelated to medical therapy), and\u002For active thromboembolism (initiated on systemic anticoagulation in the last 3 months). The rationale for this criterion is that patient presenting for initial therapy for uncontrolled nephrotic syndrome may need to be initiated on various medications including immunosuppressives as well as non-immunosuppressive drugs which can significantly change the level of proteinuria. Additionally, fluid shifts due to diuretic use for treating edema can alter GFR which could confound the pharmacokinetics and pharmacodymanics of the investigational drug.\n* Individuals who acutely require optimization of volume status with intravenous diuretics to control volume overload, as this may result in fluid shifts between the intravascular space and the remainder of extracellular fluid volume. This might alter drug pharmacokinetics and pharmacodynamics as mentioned above in # 2.\n* Individuals with a psychiatric illness or neurological disease that in the judgement of the investigators would interfere with the ability to adhere with the requirements of this protocol. This includes, but is not limited to, uncontrolled\u002Funtreated psychotic depression, bipolar disorder, schizophrenia, substance abuse or dependence, antisocial personality disorder, panic disorder, or behavioral problems, which might interfere with effective communication.\n* Vulnerable individuals, including those with impaired cognitive function or are incarcerated.\n* Individuals whose renal biopsy shows evidence of an additional pathology along with FSGS.\n* Renal biopsy showing interstitial fibrosis and tubular atrophy (IFTA) \\>50% per biopsy report.\n* Individuals with uncontrolled hypertension with blood pressures consistently \\>140\u002F90 mmHg on 3 or more community clinic blood pressure measurements.\n* Individuals with clinical evidence of any type of active infection including but not limited to HIV, Hepatitis B and\u002For Hepatitis C or patients who are positive on screening test for HIV including antibody or viral load, HBV surface antigen and\u002For HCV antibody. If a patient is positive for HCV antibody, then an HCV viral load will be measured to identify subjects with active infection. Additional tests may include those to screen for active CMV, Infectious Mononucleosis (Epstein-Barr Virus), parvovirus B19 and\u002For COVID-19 infection as per investigator judgement.\n* Individuals with evidence and\u002For documented history of progressive deterioration of liver functions, including the production of clotting factors, removal of toxic metabolic products, bile excretion for at least 6 months, routine hepatic laboratory indices including but not limited to (AST, ALT, or GGT) greater than 3 times the upper limit of normal, and\u002For individuals with a documented history and\u002For diagnosis of chronic liver disease.\n* Individuals with hypertriglyceridemia \\>500 mg\u002FdL.\n* Individuals with a documented history of malignancy (identified in last 5 years or on active therapy at time of screening).\n* Individuals with a documented history of Type I or Type II Diabetes Mellitus\n* Individuals with documented history of hematological conditions commonly associated with FSGS such as sickle cell disease and myeloproliferative disorders.\n* Individuals with a documented history of cardiac conditions commonly associated with FSGS such as congenital cyanotic heart disease. Individuals with a documented history of connective tissue disorders commonly associated with FSGS such as SLE and multiple sclerosis.\n* Individuals taking medications (either currently or within the last 6 months) associated with FSGS such as interferons, lithium, androgenic steroids, sirolimus, heroin, anthracyclines and bisphosphonates.\n* Individuals who are pregnant, will be breastfeeding or refuse birth control anytime during the study.\n* Individuals who have received treatment with another investigational drug, investigational device, or approved therapy for investigational use less than 60 days prior to planned ManNAc dosing.\n* Individuals with hypersensitivity to ManNAc.\n* Individuals who have been treated with ManNAc, sialic acid, IVIG, and\u002For other supplements containing sialic acid (e.g., sialyllactose) less than 60 days prior to planned ManNAc dosing.\n* Individuals who received a renal or any other solid organ and\u002For bone marrow\u002Fstem cell transplantation.\n* Individuals who in the judgment of the investigator, have a condition that places the subject at increased risk for AEs or has any other illness or clinical condition that might confound the results of the study or pose an additional risk in administering study drug to the subject.\n* Patients who need systemic immunosuppressive or glucocorticoid therapy for non-renal indication at any time throughout the trial.\n* Any patient receiving rituximab, cyclosphosphamide and\u002For plasmapheresis within 6 months of screening.\n* A documented history of active alcohol and\u002For substance abuse within the past 2 years.\n* Any patient with collapsing FSGS variant on renal biopsy.\n* Individuals with clinical history suggesting a post-adaptive FSGS such as those with neonatal history of low birth weight, congenital anomaly of the kidney or urinary tract (CAKUT) based on renal ultrasound findings or history of nephrectomy, vesicoureteral reflux or obesity as defined by Body Mass Index (BMI) \\> 40kg\u002Fm\\^2.","ALL","18 Years","115 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Background:\n\nFocal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed.\n\nObjective:\n\nTo test a study drug (ManNAc) in people with FSGS.\n\nEligibility:\n\nPeople aged 18 years and older with FSGS.\n\nDesign:\n\nParticipants will have 5 to 6 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights.\n\nManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse effects or troubles they have using the drug at home.\n\nDuring clinic visits, participants will have physical exams with blood and urine tests. They will complete questionnaires about their health, sleep habits, and fatigue symptoms.\n\nDuring overnight visits, participants will also have 24-hour urine collection.\n\nA study team member will call participants 1 week after the first dose to check on their health. Follow-up phone calls will then be every 2 weeks after each clinic visit.\n\nParticipants may meet with a dietitian to discuss nutrition while taking the ManNAc.\n\nParticipants may choose to have genetic tests.",[26],"Focal Segmental Glomerulosclerosis",[28,29,30,31,32],"FSGS","ManNAc","Sialic Acid","Proteinuria","Kidney Disease","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":20},"2026-07-16",{"date":41,"type":20},"2027-12-01",{"name":43,"class":44},"National Human Genome Research Institute (NHGRI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100053231","phase-2-a-study-of-praliciguat-in-participants-with-focal-segmental-glomerulosclerosis-fsgs-100053231","NCT07268638","A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis","Inclusion Criteria:\n\n1. UPCR ≥1 (g\u002Fg) during screening.\n2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent.\n3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n4. Kidney biopsy collected within 5 years of screening consistent with FSGS or kidney biopsy collected ≥5 years prior to screening consistent with FSGS plus the presence of a pathogenic gene mutation known to be associated with FSGS.\n\nExclusion Criteria:\n\n1. Collapsing FSGS in the kidney biopsy report.\n2. Sickle cell disease.\n3. HbA1c \\>8%.\n4. Uncontrolled hypertension (≥160\u002F100 millimeters of mercury).",{"count":54,"type":20},60,[23],"This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.",[26],[59,60,31,61],"Glomerular Disease","Chronic Kidney Disease","Urine protein-to-creatinine ratio",{"date":36,"type":37},{"date":64,"type":37},"2025-12-03",{"date":66,"type":20},"2028-01",{"name":68,"class":69},"Akebia Therapeutics","INDUSTRY",23,{"id":72,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":24,"conditions":75,"keywords":76,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":45},"100567179",{"count":19,"type":20},[23],[26],[28,29,30,31,32],"2026-07-01",{"date":79,"type":37},"2026-07-02",{"date":81,"type":20},"2026-07-07",{"date":41,"type":20},{"name":43,"class":44},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":15,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100609861","phase-3-a-study-to-find-out-if-bi-764198-helps-adults-and-adolescents-with-a-kidney-condition-called-focal-segmental-glomerulosclerosis-fsgs-100609861","NCT07220083","A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)","A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants","Inclusion criteria:\n\n1. Male or female participants ≥12 years old on the day of signing informed consent\u002Fassent (Visit 1)\n2. Weight of ≥40 kg at the screening visit (Visit 1)\n3. Body mass index (BMI) of ≤40 kg\u002Fm² at the screening visit (Visit 1)\n4. Participants with a diagnosis prior to the screening visit (Visit 1) of either:\n\n   * Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR\n   * Genetic focal segmental glomerulosclerosis (FSGS) resulting from a gain-of-function mutation in the transient receptor potential cation subfamily C member 6 (TRPC6) gene (based on historical genetic test)\n5. Urine protein-creatinine ratio (UPCR) ≥1500 mg\u002Fg based on the mean of the spot urine sample and first morning void urine sample (both assessed by central laboratory) at the screening visit (Visit 1)\n6. Estimated glomerular filtration rate (eGFR)\n\n   * For adult participants (≥18 years): ≥25 mL\u002Fmin\u002F1.73 m² (chronic kidney disease epidemiology collaboration (CKD-EPI) formula based on combined serum creatinine plus cystatin C) at the screening visit (Visit 1)\n   * For adolescent participants (12 to \\\u003C18 years); ≥25 mL\u002Fmin\u002F1.73 m² based on chronic kidney disease under 25 years (CKiD U25) formula using height and serum cystatin C at the screening visit (Visit 1) Further inclusion criteria apply.\n\nExclusion criteria:\n\n1. Known monogenic or syndromic causes of FSGS (with the exception of TRPC6 gain-of-function gene mutations)\n2. Clinical or histologic evidence of secondary maladaptive or toxic forms of FSGS (based on Investigator's judgement)\n3. FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)\n4. A history of organ transplantation or planned organ transplantation during the course of the trial\n5. Use of intravenous immunosuppressive agents (e.g. cyclophosphamide, rituximab, obinutuzumab) in the last 6 months prior to screening (Visit 1) Further exclusion criteria apply.","12 Years",{"count":93,"type":20},286,[95],"PHASE3","This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.\n\nParticipants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.\n\nParticipants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.\n\nParticipants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.",[26],"2026-06-22",{"date":100,"type":37},"2026-06-23",{"date":102,"type":37},"2026-02-16",{"date":104,"type":20},"2029-01-24",{"name":106,"class":69},"Boehringer Ingelheim",287,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":131,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":146},"100406380","neptune-match-study-100406380","NCT04571658","NEPTUNE Match Study","Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)","NEPTUNE Match","Inclusion Criteria:\n\n1. Consented and eligible participants in the biopsied or non-biopsied cohorts of the NEPTUNE observational study\n2. Must be potentially eligible for the NEPTUNE Match partnering trials (e.g. if no trial is enrolling a participant under age 6, those under 6 are not eligible).\n\n   Note: NEPTUNE Match partnering trials and associated eligibility criteria are expected to be dynamic and change as trial protocols are developed, activated, and amended.\n3. Regular nephrology healthcare provided at a NEPTUNE study site.\n4. Willing and able to consent, and as appropriate assent, to participate in NEPTUNE Match\n\nExclusion Criteria:\n\nCurrently non-NEPTUNE observational study participants are not eligible to be matched to a clinical trial using these biomarker assessments.\n\nExclusion Criteria:\n\n1\\. Non-English or non-Spanish speaking","1 Year","80 Years",{"count":119,"type":20},375,[121],"NA","NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.",[124,26,125,126,127,28,128,129,130],"Nephrotic Syndrome in Children","Minimal Change Disease","Minimal Change Nephrotic Syndrome","Membranous Nephropathy","MCD","MCD - Minimal Change Disease","Alport Syndrome",[132,133,134,135],"Nephrotic Syndrome","NEPTUNE","Match","Clinical Trial Match","2026-06-08",{"date":138,"type":37},"2026-06-10",{"date":140,"type":37},"2022-05-02",{"date":142,"type":20},"2029-12-30",{"name":144,"class":145},"University of Michigan","OTHER",16,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100554562","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-frexalimab-brivekimig-or-rilzabrutinib-in-participants-aged-16-to-75-years-with-primary-focal-segmental-glomerulosclerosis-or-minimal-change-disease-100554562","NCT06500702","A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease","A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)","RESULT","Inclusion Criteria:\n\n* Biopsy report indicative of primary FSGS or primary MCD, with supportive clinical presentation per Investigator's judgement.\n* UPCR ≥3 g\u002Fg at screening, or ≥ 1.5 g\u002Fg in those with eGFR ≥ 60.\n* eGFR ≥45 mL\u002Fmin\u002F1.73 m\\^2 at screening.\n* Documented history of UPCR (or 24-hour urine protein) reduction by \\>40% in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥3.5 g\u002Fg (or pre-treatment 24-hr urine protein was ≥3.5 g\u002Fday if 24-hour urine protein is used).\n* ≤10 mg\u002Fday prednisone or equivalent and stable starting at least 1 week prior to randomization.\n* For those on a RAAS inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting RAAS inhibitors or changing the dose will not be allowed during the double-blind or OLE treatment period.\n* For those on an SGLT2 inhibitor prior to screening, the dose must be stable ≥4 weeks prior to screening; starting SGLT2 inhibitor treatment or changing the dose will not be allowed during the double-blind or OLE treatment periods.\n* Body weight within 45 to 120 kg (inclusive) at screening.\n\nExclusion Criteria:\n\n* Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.\n* Collapsing variant of FSGS.\n* ESKD requiring dialysis or transplantation.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","16 Years","75 Years",{"count":158,"type":20},84,[23],"This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).\n\nThe purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years.\n\nStudy details for each participant include:\n\nThe study duration will be up to 76 weeks. The treatment duration will be 24 weeks. There will be up to 18 visits.",[26,162],"Glomerulonephritis Minimal Lesion","2026-06-04",{"date":136,"type":37},{"date":166,"type":37},"2024-12-19",{"date":168,"type":20},"2028-02-16",{"name":170,"class":69},"Sanofi",71,{"id":173,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":56,"conditions":177,"keywords":178,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":184,"locationsCount":185},"100613595","Inclusion Criteria:\n\n1. UPCR ≥1 (g\u002Fg) during screening.\n2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent.\n3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n4. Kidney biopsy within 3 years of screening consistent with FSGS or documentation of a genetic mutation in a podocyte protein associated with FSGS.\n\nExclusion Criteria:\n\n1. Collapsing FSGS in the kidney biopsy report.\n2. Sickle cell disease.\n3. HbA1c \\>8% or non-fasting blood glucose \\>180 milligram\u002Fdecilitre.\n4. Uncontrolled hypertension (≥160\u002F100 millimeters of mercury)",{"count":54,"type":20},[23],[26],[59,60,31,61],"2026-06-03",{"date":181,"type":37},"2026-06-05",{"date":64,"type":37},{"date":66,"type":20},{"name":68,"class":69},14,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":116,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100439568","phase-2-study-of-sparsentan-treatment-in-pediatrics-with-proteinuric-glomerular-diseases-100439568","NCT05003986","Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases","A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases","EPPIK","Inclusion Criteria for All Subjects (All Three Populations):\n\nA subject must meet all of the following criteria to be eligible for participation in this study:\n\n* The subject or parent\u002Flegal guardian (as appropriate) is willing and able to provide signed informed consent\u002Fassent, and where required, the subject is willing to provide assent before any screening procedures per local requirements.\n* The subject has an estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73 m2 at screening.\n* The subject has a mean seated blood pressure between the 5th and 95th percentile for sex and height.\n\nInclusion Criteria for Population 1:\n\n* The subject is male or female ≥1 year at screening and \\\u003C18 years of age at Day 1 (Baseline).\n* The subject has a UP\u002FC ≥1.5 g\u002Fg (170 mg\u002Fmmol) at screening AND one of the following:\n* Kidney biopsy-proven FSGS or MCD histological patterns and clinical presentation consistent with primary FSGS or MCD and qualifying proteinuria at screening despite history or ongoing treatment with corticosteroids and\u002For other immunosuppressive disease-modifying agents.\n* Documentation of a genetic mutation in a podocyte protein associated with FSGS or MCD. Subjects with a documented podocytic mutation do not require kidney biopsy.\n* Kidney biopsy-proven FSGS histological pattern with medical history and clinical presentation consistent with maladaptive cause of the lesion.\n\nNote: The kidney biopsy may have been performed at any time in the past but must include light microscopy and electron microscopy characteristics and\u002For immunofluorescence findings consistent with FSGS or MCD.\n\nInclusion Criteria for Population 2:\n\n* The subject is male or female ≥2 years at screening and \\\u003C18 years of age at Day 1 (Baseline).\n* The subject has UP\u002FC ≥0.6 g\u002Fg (68 mg\u002Fmmol) at screening AND one of the following diagnoses:\n* Kidney biopsy-confirmed IgAN, IgAV, or AS\n* Diagnosis of AS by genetic testing (pathogenic X-linked Collagen, Type IV, Alpha-5 (COL4A5) mutation OR autosomal-recessive mutations in both alleles of Collagen, Type IV, Alpha-3 (COL4A3) and\u002For Collagen, Type IV, Alpha-4 (COL4A4) OR autosomal-dominant COL4A3 and\u002For COL4A4 and digenic mutations \\[ie, simultaneous mutations in 2 of the COL4A3, COL4A4, and COL4A5 genes\\])\n\nInclusion Criteria for Population 3:\n\n* The subject is male or female ≥8 years at screening and \\\u003C18 years of age at Day 1 (Baseline).\n* The subject has UP\u002FC ≥1.0 g\u002Fg (113 mg\u002Fmmol) at screening AND has kidney biopsy-confirmed IgAN\n* Subject weighs ≥40 kg\n* The subject has been on ACEI and\u002For ARB therapy for at least 12 weeks prior to screening\n\nExclusion Criteria for All Subjects (All Three Populations):\n\nA subject who meets any of the following will be excluded from this study:\n\n* The subject weighs \\\u003C7.3 kg at screening.\n* The subject has FSGS or MCD histological pattern secondary to viral infections, drug toxicities, or malignancies.\n* The subject has immunoglobulin A (IgA) glomerular deposits not in the context of primary IgAN or IgAV (ie, secondary to another condition; eg, systemic lupus erythematosus and liver cirrhosis).\n* The subject has had an acute onset or presentation of glomerular disease or a diagnostic biopsy or a relapse of glomerular disease requiring new or different class of immunosuppressive treatment (including, but not limited to, systemic corticosteroids, calcineurin inhibitors and mycophenolate mofetil, abatacept, cyclophosphamide, rituximab, ofatumumab, and ocrelizumab) within 6 months before screening.\n* Subjects taking chronic immunosuppressive medications (including systemic steroids) not on a stable dose for ≥1 month before screening.\n* The subject requires any of the prohibited concomitant medications as defined in the study protocol.\n* The subject has undergone any organ transplantation, with the exception of corneal transplants.\n* The subject has a documented history of congenital or acquired heart failure (modified Ross heart failure classification for children Class II to Class IV) and\u002For previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, and\u002For peripheral edema.\n* The subject has hemodynamically significant cardiac valvular disease.\n* The subject has clinically significant congenital vascular disease.\n* The subject has jaundice, hepatitis, or known hepatobiliary disease, or alanine aminotransferase and\u002For aspartate aminotransferase \\>2 times the upper limit of the normal range at screening.\n* The subject has a history of malignancy within the past 2 years.\n* The subject has a screening hematocrit \\\u003C27% (0.27 L\u002FL) or a hemoglobin value \\\u003C9 g\u002FdL (90 g\u002FL).\n* The subject has a screening potassium value \\>5.5 milliequivalent (mEq)\u002FL (5.5 mmol\u002FL).\n* The subject has any abnormal clinical laboratory screening values that are considered by the Investigator to be clinically significant.\n* The subject has a history of allergic response to any angiotensin II antagonist or endothelin receptor antagonist, including sparsentan, or has a hypersensitivity to any of the excipients in the study medication.\n* The female subject is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.\n* Female subjects of childbearing potential, beginning at menarche, who do not agree to use 1 highly reliable (ie, can achieve a failure rate of \\\u003C1% per year) method of contraception from 7 days before the first dose of the study medication until 28 days after the last dose of study medication. Examples of highly reliable contraception methods include stable oral, implanted, transdermal, or injected contraceptive hormones associated with the inhibition of ovulation or an intrauterine device. One additional barrier method must also be used during vaginal sexual activity, such as a diaphragm, diaphragm with spermicide (preferred), or male partner's use of male condom or male condom with spermicide (preferred), from Day 1\u002FRandomization until 28 days after the last dose of study medication. Female subjects of childbearing potential are defined as those who are fertile after menarche, unless permanently sterile; permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. All female subjects of childbearing potential must have a negative serum pregnancy test result at screening (Visit 1) and a negative urine pregnancy test result, with positive results confirmed by serum, at every study visit from Day 1 (Visit 3) and after.\n\nNote: Before menarche, pregnancy testing and contraceptive use are not required. However, subjects and their parents\u002Flegal guardians must be advised that, immediately upon menarche, subjects will be required to begin pregnancy testing and initiate contraceptive use. This requirement cannot be waived.\n\n* The subject has participated in a study of another study medication within 28 days before screening or plans to participate in such a study during the course of this study.\n* The subject has had prior exposure to sparsentan.\n* The subject or parent\u002Flegal guardian (as appropriate), in the opinion of the Investigator, are unable to adhere to the requirements of the study including but not limited to, a history of noncompliance and\u002For any other reason that causes the Investigator to believe the subject would not be a good candidate for the study.\n* For Population 3 - the subject is unable to swallow the study medication tablets whole.","17 Years",{"count":196,"type":20},67,[23],"To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.",[26,125,200,201,130],"Immunoglobulin A Nephropathy","IgA Vasculitis",[203],"Alport, AS, FSGS, IgAN, IgAV, MCD, pediatrics, peds","2026-05-08",{"date":206,"type":37},"2026-05-12",{"date":208,"type":37},"2021-08-12",{"date":210,"type":20},"2027-04-12",{"name":212,"class":69},"Travere Therapeutics, Inc.",47,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":45},"100489246","recurrence-post-transplant-observational-study-in-focal-segmental-glomerulosclerosis-and-minimal-change-disease-100489246","NCT05650619","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)","RESOLVE","Inclusion Criteria:\n\n* Retrospective non-consented participant group had a transplant from the year 2000 and onward.\n* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).\n\nExclusion Criteria:\n\n* Pathologic diagnosis other than FSGS or MCD\n* FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)",{"count":223,"type":20},300,"OBSERVATIONAL","The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes.\n\nThe purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.",[26,125,28,128],[228,229,230,231,232],"Kidney disease","Kidney transplant","Adult","Children","Recurrence","2026-04-23",{"date":235,"type":37},"2026-04-29",{"date":237,"type":37},"2022-12-08",{"date":239,"type":20},"2027-12",{"name":144,"class":145},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":249,"maxAge":194,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100484123","a-pilot-trial-of-tavns-for-srns-in-children-kidney-vns-100484123","NCT05583942","A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)","A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Steroid Resistant Nephrotic Syndrome in Children","kidNEY-VNS","Inclusion Criteria:\n\n* Steroid Resistant Nephrotic Syndrome- defined as lack of remission after 4 weeks of therapy of prednisolone\u002Fprednisone at standard dose1\n* Age 3-17 years\n* eGFR ≥30 ml\u002Fmin\u002F1.73 m2 (by modified Schwartz formula)\n* MCD or FSGS diagnosis (per biopsy)\n* Urine protein:creatinine (UPC) greater than 1.0\n* Stable immunosuppression and ACE inhibitor\u002Fangiotensin receptor blocker treatment regimen for at least three months\n* Evidence of B cell repletion for those exposed to rituximab\n* Informed consent from the parent or guardian and assent from a minor of ≥ 7 years\n* Ability to comply with the study protocol, in the investigator's judgment\n\nExclusion Criteria:\n\n* Secondary causes of nephrotic syndrome (e.g. genetic, congenital, infectious)\n* Steroid sensitive nephrotic syndrome\n* History of genetic defects known to directly cause nephrotic syndrome (i.e., NPHS2 \\[podocin\\], NPHS1 \\[nephrin\\], PLCE1, WT1, or other known genetic cause)\n* Any known inflammatory condition\n* History of cardiac disease (arrhythmias, structural\u002Ffunctional abnormalities)\n* Implantable electronic devices (pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators)\n* Chronic rash or skin breakdown of the left ear at the cymba concha\n* Pregnancy","3 Years",{"count":251,"type":20},10,[121],"Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.",[124,125,26],[256,257,258],"vagus nerve stimulation","pediatric","nephrology","2026-04-14",{"date":261,"type":37},"2026-04-17",{"date":263,"type":37},"2022-09-19",{"date":265,"type":20},"2027-08-01",{"name":267,"class":145},"Northwell Health",2,{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":247,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":15,"minAge":249,"maxAge":194,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":268},"100484439","tavns-for-frns-in-children-100484439","NCT05588063","taVNS for FRNS in Children","A Pilot Randomized Clinical Trial of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children","Inclusion Criteria:\n\n* FRNS\n* Age 3-17 years\n* Glomerular filtration rate (eGFR) ≥30 ml\u002Fmin\u002F1.73 m2\n* Minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) diagnosis (clinical diagnosis or per biopsy)\n* Steroid sensitive nephrotic syndrome (prior history of remission within 4 weeks of steroid therapy)\n* In remission at time of enrollment (remission defined as UPC \\\u003C0.2 or negative dipstick for 3 consecutive days)\n* Informed consent from the parent or guardian and assent from a minor of ≥ 7. years\n\nExclusion Criteria:\n\n* Secondary forms of nephrotic syndrome\n* SRNS\n* Steroid dependent nephrotic syndrome (relapse within 14 days of stopping steroids or relapse while on steroids)\n* Exposure to steroids within 14 days of enrollment\n* Receiving any standing immunosuppression (previous exposure \\> 2 months allowed and\u002For B cell repletion)\n* Any known inflammatory condition (e.g. systemic lupus erythematosis)\n* History of cardiac disease (arrhythmias, structural\u002Ffunctional abnormalities)\n* Implantable electronic devices\n* Pregnancy\n* Participants\u002Fguardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures",{"count":19,"type":20},[121],"Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.",[124,125,26],[256,257,258],{"date":282,"type":37},"2026-04-15",{"date":284,"type":37},"2023-01-05",{"date":265,"type":20},{"name":267,"class":145},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":117,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":268},"100523023","phase-1-ampk-activation-by-metformin-in-fsgs-amp-fsgs-100523023","NCT06090227","AMPK-activation by Metformin in FSGS: AMP-FSGS","AMP-FSGS","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged greater than or equal to 18 years, but \\\u003C\u002F= 80 years age at the time of signing the informed consent\n4. Biopsy-confirmed primary FSGS as defined by expert renal pathology at either institutions. For homogeneity of diagnoses, demonstrable segmental or global sclerosis lesions (\\>\u002F=1 glomerulus) with diffuse podocyte foot process effacement by electron microscopy (\\>\u002F+ 50% of examined glomerular tufts), or show evidence of mesangial expansion or mesangial sclerosis, also confirmed by electron microscopy.\n5. Therapeutic plan by treating physician for immunomodulatory treatment using Glucocorticoids.\n6. Ability to take oral medication and be willing to adhere to the MF or Placebo regimen\n7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of VPA administration. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.\n\nExclusion Criteria:\n\n1. Liver disease: confirmed cirrhosis liver (any stage), acute hepatitis (\\> 2 fold increase in liver enzymes, any coagulopathy, hyperbilirubinemia, ascites or encephalopathy)\n2. estimated GFR \\\u003C 32 ml\u002Fmin\n3. Diabetes Mellitus diagnosis at the time of biopsy or need for oral hypoglycemic agents\u002FInsulin, or taking Metformin for other indications\n4. Treatment with another investigational drug or other intervention within 3 months\n5. Current pregnancy or desire to become pregnant during the study period\n6. Unwilling to use two forms of birth control (for women of childbearing age)\n7. Under hospice care\n8. Confirmed Dementia diagnoses in EMR problem list\n9. Incarceration\n10. Homelessness\n11. Inability to consent\n12. Currently enrolled in (or completed within the past 30 days) a study of an investigational drug or device.\n13. Life expectancy of less than 6 months as determined by the clinical judgement of the patient's primary physician\n14. Allergy or sensitivity to Metformin\n15. Platelet count \\\u003C 100,000\u002FµL; INR \\> 1.5; Bleeding diathesis or blood thinner use contraindicating biopsy.\n16. Bleeding diathesis or blood thinner use contraindicating biopsy will be excluded entirely from participation in research biopsy portion of study only, even if anticoagulation\u002Fblood thinners can be held temporarily.\n17. Simultaneous use of Carbonic anhydrase inhibitor agents\n18. Use of systemic immunosuppressive medication for non-renal indications",{"count":19,"type":20},[296,23],"PHASE1","The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).",[26],"2026-01-30",{"date":301,"type":37},"2026-02-03",{"date":303,"type":37},"2023-12-14",{"date":305,"type":20},"2027-11",{"name":307,"class":145},"Yale University",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100227240","post-approval-study-of-liposorber-la-15-system-for-the-treatment-of-focal-segmental-glomerulosclerosis-in-children-100227240","NCT02235857","Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children","Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System","FSGS pediatric","Inclusion Criteria:\n\n* A pediatric patient is deemed suitable for inclusion in the study if the patient has FSGS with a GFR ≥ 45 ml\u002Fmin\u002F1.73 m 2 and any of the following:\n\n  * Refractory nephrotic syndrome in which standard treatment options are unsuccessful (i.e., patient is unresponsive to standard corticosteroid and\u002For calcineurin inhibitor therapy for at least 8 weeks resulting in failure to achieve complete or partial remission);\n  * Refractory nephrotic syndrome in which standard treatment options are not well tolerated (i.e., patients intolerant to standard therapies due to severe side effects that negatively affect quality of life without providing an acceptable level of clinical benefit);\n  * Refractory or recurrent nephrotic syndrome in which standard therapy is contraindicated.\n\nor\n\n\\- Pediatric post renal transplant patients with nephrotic syndrome associated with primary FSGS.\n\nExclusion Criteria:\n\n* General Exclusion Criteria\n\n  * Patient is greater than 21 years of age\n  * Parent or patient is unwilling or unable to sign and date the informed consent (Note: Only patients 18-21 years of age may sign the informed consent on their own behalf)\n  * Pregnant, lactating, or planning to become pregnant prior to completing the study (Note: The safety of the use of Liposorber® in pregnant women has not been studied. There may be unknown risks to an embryo\u002Ffetus. Sexually active women of child bearing potential should avoid pregnancy during the use of the Liposorber device and throughout the study duration.)\n  * Unable or unwilling to comply with the follow-up schedule\n  * Simultaneously participating in another investigational drug or device study\n  * Body weight \\\u003C 15 kg (33.1 lbs)\n* Medical Exclusion Criteria\n\n  * Currently being administered ACE inhibitors that cannot be withheld for at least 24 hours prior to each apheresis treatment (Note: The time period to withhold ACE inhibitors should be prolonged, if determined by the treating physician, considering each individual's renal function and the biological half-life of the ACE-inhibitor currently in use.)\n  * Currently being administered antihypertensive drugs other than ACE inhibitors (e.g., Angiotensin II receptor blockers (ARBs) that cannot be withheld on the day of apheresis until after the procedure\n  * Medical condition or disorder that would limit life expectancy to less than the primary clinical study endpoint or that may cause noncompliance with the study plan or confound the data analysis\n  * Hypersensitivity to dextran sulfate, heparin, or ethylene oxide\n  * Adequate anticoagulation cannot be achieved due to severe hemophilia, severe hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of vitamin K antagonist medications\n  * Extracorporeal circulation therapy with Liposorber® LA-15 System cannot be tolerated due to severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or severe uncontrollable hypotension\n  * Cardiac impairments such as uncontrolled arrhyth¬mia, unstable angina, decompensated congestive heart failure, or valvular disease\n  * Functional thyroid disease or liver abnormalities\n  * Unresolved systemic or local infection that could affect the clinical study outcomes","21 Years",{"count":318,"type":20},35,[121],"Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia).\n\nAlthough the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology.\n\nThis study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.",[26],[323],"pediatric, renal transplantation, recurrence, drug-resistant","2025-04-29",{"date":326,"type":37},"2025-04-30",{"date":328,"type":37},"2015-05-03",{"date":330,"type":20},"2028-07-03",{"name":332,"class":69},"Kaneka Medical America LLC",12,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":341,"sex":15,"minAge":16,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":45},"100511683","phase-1-a-first-in-human-study-to-evaluate-safety-tolerability-pharmacology-of-hs-10390-in-healthy-subjects-100511683","NCT05942625","A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects","A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects","Inclusion Criteria:\n\n* Healthy male or female subjects between the ages of 18-45 years\n* Have no reproductive potential; or agree to use a highly effective method ofcontraception, and refrain from donating sperm or eggs during the study period and forat least 6 months after last dosing\n* Have signed the informed consent form approved by the IRB\n\nExclusion Criteria:\n\n* History or evidence of clinically significant cardiovascular, pulmonary, endocrine,gastrointestinal, psychiatric, neurologic, hematological or metabolic diseases, especiallythose conditions that interfere with absorption, metabolism and\u002For excretion of the studydrug, determined by the investigator\n* Have a clinically significant infection currently or within past 30 days, or have a history ofactive tuberculosis; or have positive screening test for infectious disease, includingtuberculosis, viral hepatitis, AIDS and syphilis\n* Have a history of or current allergic disease\n* Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol ordrugs of abuse\n* Smokers smoked ≥5 cigarettes per day within past 3 months or have a positive test resultfor nicotine\n* Clinically significant abnormal physical examination, vital signs, clinical laboratory values,ECGs or imaging tests\n* Pregnant or breastfeeding female subjects",true,"45 Years",{"count":158,"type":20},[296],"The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.",[347,26],"IgA Nephropathy",[349,350,351,352,353],"HS-10390","Safety","Tolerability","Pharmacokinetics","Pharmacodynamics","2024-10-07",{"date":356,"type":37},"2024-10-09",{"date":358,"type":37},"2023-05-23",{"date":360,"type":20},"2024-12-30",{"name":362,"class":69},"Hansoh BioMedical R&D Company",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":156,"enrollmentInfo":371,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":251},"100367526","post-approval-study-for-treatment-of-drug-resistant-adult-and-pediatric-primary-fsgs-using-the-liposorber-la-15-system-100367526","NCT04065438","Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System","Treatment of Drug-resistant Adult and Pediatrc Primary Focal Segmental Glomerulosclerosis and Post -Transplant Recurrence Using the LIPOSORBER® LA-15 System","FSGSALLAGE","Inclusion Criteria:\n\nA patient is deemed suitable for inclusion in the study if the patient has nephrotic syndrome associated with primary FSGS when:\n\n• Standard treatment options, including corticosteroid and\u002For calcineurin inhibitors, are unsuccessful or not well tolerated and the patient's glomerular filtration rate (GFR) ≥ 45 ml\u002Fmin\u002F1.73 m2.\n\nor\n\n• The patient is post renal transplantation.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria\n\n1. Patient is greater than 75 years of age at the start of the treatment period or less than 22\n2. The patient is unwilling or unable to sign and date the informed consent\n3. Pregnant, lactating, or planning to become pregnant prior to completing the study (Note: The safety of the use of LIPOSORBER® in pregnant women has not been studied. There may be unknown risks to an embryo\u002Ffetus. Sexually active women of childbearing potential should avoid pregnancy during the use of the LIPOSORBER device and throughout the study duration.)\n4. Unable or unwilling to comply with the follow-up schedule\n5. Simultaneously participating in another investigational drug or device study\n6. Body weight \\\u003C 15 kg (33.1 lbs)\n\nMedical Exclusion Criteria\n\n1. Currently being administered ACE inhibitors that cannot be withheld for at least 24 hours prior to each apheresis treatment (Note: The time period to withhold ACE inhibitors should be prolonged, if determined by the treating physician, considering each individual's renal function and the biological half-life of the ACE-inhibitor currently in use.)\n2. Currently being administered antihypertensive drugs other than ACE inhibitors (e.g., ARBs) that cannot be withheld on the day of apheresis until after the procedure\n3. Medical condition or disorder that would limit life expectancy to less than the primary clinical study endpoint or that may cause noncompliance with the study plan or confound the data analysis\n4. Hypersensitivity to dextran sulfate, heparin, or ethylene oxide\n5. Adequate anticoagulation cannot be achieved due to severe hemophilia, severe hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of vitamin K antagonist medications\n6. Extracorporeal circulation therapy with LIPOSORBER® LA-15 System cannot be tolerated due to severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or severe uncontrollable hypotension Note: Severe uncontrollable hypotension\u002Fhypertension indicates the cases with systolic and\u002For diastolic blood pressure ≤ 5th percentile for age, gender, and height.\n7. Cardiac impairments such as uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure, or valvular disease\n8. Functional thyroid disease or liver abnormalities\n9. Unresolved systemic or local infection that could affect the clinical study outcomes",{"count":318,"type":20},[121],"This multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and\u002For calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml\u002Fmin\u002F1.73m2, or the patient has post-renal transplant recurrence. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.",[26],[28,376],"Liposorber",{"date":356,"type":37},{"date":379,"type":37},"2020-01-01",{"date":381,"type":20},"2028-06-01",{"name":332,"class":69},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":403,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":45},"100550127","predictive-determinants-of-nephrotic-syndrome-remission-in-patients-with-at-risk-polymorphism-of-apol1-100550127","NCT06443034","Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1","Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene","NEPHROL1","Inclusion Criteria:\n\n* Adult patients followed in 6 nephrology centers between 01\u002F01\u002F2016 and 01\u002F06\u002F2024.\n* With characterization of APOL1 gene risk status\n* Proteinuria\u002Fcreatinuria ratio \\> 3 g\u002Fg at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)\n* Hypoalbuminemia \\\u003C 30 g\u002FL at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)\n* Minimal change disease or segmental and focal hyalinosis lesions on renal biopsy.\n\nExclusion Criteria:\n\n* Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study\n* Presence of endo- or extracapillary hypercellular lesions on light microscopy\n* Opposition to the use of medical data",{"count":392,"type":20},124,"This is a multicentric retrospective observational cohort study.\n\nAs primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.\n\nAs secondary objectives, this study aims:\n\n* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome\n* To identify the predictors of complete renal remission of nephrotic syndrome\n* To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease\n* To assess the adverse events of corticosteroids in patients treated with corticosteroids.",[132,26,395],"APOL1 Associated Kidney Disease",[397,398,399,400,401,402],"Nephrotic syndrome","Covid-19 associated nephropathy","human immunodeficiency virus associated nephropathy","APOL1 associated kidney disease","Focal segmental glomerulosclerosis","Minimal change disease","NOT_YET_RECRUITING","2024-06-03",{"date":406,"type":37},"2024-06-05",{"date":408,"type":20},"2024-06-30",{"date":360,"type":20},{"name":411,"class":145},"Assistance Publique - Hôpitaux de Paris",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":156,"enrollmentInfo":418,"targetDuration":420,"studyType":224,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":45},"100528574","arrest-nephrosis---austrian-resistant-nephrotic-syndrome-treatment-response-registry-and-biobank-100528574","NCT06162546","ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank","Inclusion Criteria:\n\n* Resistant to standard Immunosuppressive agents (if clinically indicated, e.g. primary\u002Fnon-genetic forms)\n* Persistent urinary protein-to-creatinine (UP\u002FC) ratio \\>1.0 g\u002Fg\n* eGFR \\> 30 ml\u002Fmin per 1.73 m2\n* biopsy or a disease-causing genetic mutation associated with nephrotic syndrome\n\nExclusion Criteria:\n\n* Inability or unwillingness to comply with repeated assessments\n* Objections against participation at discretion of the investigator\n* Secondary\n* Patients with steroid-dependence\u002Ffrequently relapsing disease (but achievement of complete remission)",{"count":419,"type":20},100,"10 Years","Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function.\n\nThe AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries\n\n1. Obtaining real world data on practice patterns and outcomes\n2. Networking between affected patients, families, and clinicians.\n3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products\n4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses",[26,31,132,423],"Nephrotic Syndrome Steroid-Resistant","2023-11-30",{"date":426,"type":37},"2023-12-08",{"date":428,"type":37},"2023-01-01",{"date":430,"type":20},"2033-12-31",{"name":432,"class":145},"Christoph Aufricht",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":441,"targetDuration":443,"studyType":224,"phases":4,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":45},"100521150","national-registry-of-rare-kidney-diseases-100521150","NCT06065852","National Registry of Rare Kidney Diseases","National Registry of Rare Kidney Diseases (RaDaR)","RaDaR","* Kidney Rare Disease\n* Paeds and adults\n* Eligibility differs for each rare disease group\n* See: https:\u002F\u002Fukkidney.org\u002Frare-renal\u002Frecruitment",{"count":442,"type":20},35000,"30 Years","The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.\n\nThe purpose of this research is to:\n\n* Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition.\n* Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better.\n* Further the development of future treatments.\n\nParticipants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.",[446,447,448,449,130,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,26,483,484,485,486,487,488,489,347,490,491,492,493,494,495,496,497,498,499,127,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525],"Adenine Phosphoribosyltransferase Deficiency","AH Amyloidosis","AHL Amyloidosis","AL Amyloidosis","Atypical Hemolytic Uremic Syndrome","Autoimmune Distal Renal Tubular Acidosis","Autosomal Recessive Proximal Renal Tubular Acidosis","Autosomal Recessive Distal Renal Tubular Acidosis","Autosomal Dominant Polycystic Kidney Disease","Autosomal Recessive Polycystic Kidney Disease","Bartter Syndrome","BK Nephropathy","C3 Glomerulopathy With Monoclonal Gammopathy","C3 Glomerulopathy","Calciphylaxis","Crystalglobulinaemia","Crystal-storing Histiocytosis","Cystinosis","Cystinuria","Dense Deposit Disease","Dent Disease","Denys-Drash Syndrome","Dominant Hypophosphataemia With Nephrolithiasis and\u002For Osteoporosis","Drug Induced Fanconi Syndrome","Drug-Induced Hypomagnesemia","Drug-Induced Nephrogenic Diabetes Insipidus","Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy","Fabry Disease","Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis","Familial Primary Hypomagnesemia With Hypocalcuria","Familial Primary Hypomagnesaemia With Normocalciuria","Familial Renal Glucosuria","Fanconi Renotubular Syndrome 1","Fanconi Renotubular Syndrome 2","Fanconi Renotubular Syndrome 3","Fibrillary Glomerulonephritis","Fibromuscular Dysplasia","Generalised Pseudohypoaldosteronism Type 1","Gitelman Syndrome","Heavy-Metal-Induced Fanconi Syndrome","Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes","Hereditary Renal Hypouricemia","Hereditary Hypophosphatemic Rickets With Hypercalciuria","Hyperuricaemic Nephropathy","Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits","Inherited Renal Cancer Syndromes","Intracapillary Monoclonal IgM Without Cryoglobulin","Intraglomerular\u002FCapillary Lymphoma\u002FLeukaemia","Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type","Liddle Syndrome","Light Chain Cast Nephropathy","Light Chain Proximal Tubulopathy Without Crystals","Light Chain Proximal Tubulopathy With Crystals","Lowe Syndrome","Membranoproliferative Glomerulonephritis","Medullary Cystic Kidney Disease","Minimal Change Nephropathy","Mitochondrial Disease Of The Kidney","Monoclonal Immunoglobulin Deposition Disease","Nail Patella Syndrome","Nephrogenic Diabetes Insipidus","Nephrogenic Syndrome of Inappropriate Antidiuresis","Nephronophthisis","Primary Hypomagnesemia With Secondary Hypocalcemia","Primary Hyperoxaluria","Proliferative Glomerulonephritis With Monoclonal IgG Deposits","Proximal Tubulopathy Without Crystals","Pseudohypoaldosteronism Type 1, 2A-2E","Pure Red Cell Aplasia","Retroperitoneal Fibrosis","Sickle Cell Nephropathy","Shiga Toxin Associated Haemolytic Uraemic Syndrome","Steroid Resistant Nephrotic Syndrome","Steroid-Sensitive Nephrotic Syndrome","Thin Basement Membrane Nephropathy","Thrombotic Microangiopathy With Monoclonal Gammopathy","Type 1 Cryoglobulinaemic Glomerulonephritis","Tuberous Sclerosis","Unclassified Monoclonal Gammopathy Of Renal Significance","Vasculitis","2023-09-26",{"date":528,"type":37},"2023-10-04",{"date":530,"type":37},"2009-11-06",{"date":532,"type":20},"2039-12-31",{"name":534,"class":145},"UK Kidney Association",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":543,"targetDuration":545,"studyType":224,"phases":4,"briefSummary":546,"conditions":547,"keywords":550,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":565},"100357120","korea-renal-biobank-network-system-toward-next-generation-analysis-100357120","NCT03929887","KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis","Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research","KORNERSTONE","1. Inclusion criteria\n\n   * Patient suspected of glomerular disease who received kidney biopsy in participating university medical centers\n   * Children (age\\\u003C18 years) also included\n2. Exclusion criteria - Patients who previously received a kidney transplant",{"count":544,"type":20},3000,"20 Years","Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis is uncertain.\n\nRecently, along with advances in molecular analysis and computational bioinformatics, genomic data from human renal biopsies could provide a strong foundation for the future of precision medicine in nephrology.\n\nIn response to a request for applications by the Ministry of Health and Welfare of Korea for the creation of Clinical Research Registry, multi-center N network has been established for prospective cohort with kidney biopsy samples (KORNERSTONE).\n\nThrough this Network the investigators hope to understand the fundamental biology of glomerulonephritis and aim to bank long-term observational data and corresponding biological data including genomic data from kidney tissues, and kidney pathologic data which is digitalized This database is archived to a web-based platform to access easily and further enrich for researchers.",[59,125,347,127,26,548,549],"Lupus Nephritis","Crescentic Glomerulonephritis",[551,552,553,554,555],"Glomerular disease","sample repository","clinical data","digital pathology repository","web-based database","2020-02-10",{"date":558,"type":37},"2020-02-12",{"date":560,"type":37},"2019-05-01",{"date":562,"type":20},"2028-12-31",{"name":564,"class":145},"Seoul National University Hospital",6]